Artificial intelligence in pharmacovigilance
Several studies show that published clinical trials have major weaknesses in their reporting of side effects. Clinical trials are often too small to detect anything other than the most common side effects. Spontaneous reporting of adverse reactions depends on events being reported by healthcare professionals and there is likely to be significant under-reporting. In this webinar, Tone Westergren discusses whether knowledge about side effects can be improved by using e-health data and artificial intelligence.
Knowledge about a medicine's side effect profile comes from many sources, including clinical trials, spontaneous reports, population studies and health databases. All of these sources have clear limitations. In many cases, it has taken a long time to discover associations between disease events and drug use. There is therefore great interest in the potential for detecting adverse drug reactions in ordinary health data, where information about patients is entered continuously and can be analysed after a short time. Tone Westergren gives an introduction to the experiences, opportunities and limitations of adverse drug reaction mapping through the use of artificial intelligence on e-health data.
Tone Westergren is a pharmacist and head of section at RELIS South-East (Regional Drug Information Centre at Oslo University Hospital). She recently completed a PhD on the subject of adverse drug reactions (ADRs), including how knowledge about ADRs is produced and communicated and the weaknesses of current systems.
Recording
You can download the podcast to your mobile on Apple Podcasts, Spotify or Podbean. Search for ‘Norwegian Centre for E-health Research’.